Since higher cost of operations is a major deterrent at the moment, Indian pharma companies see the likely implications in ...

Tesla, Inc. is valued as an option on its Optimus humanoid robot project, not as a traditional automaker. Click here for more ...

XLI's 20% one-year gain reflects a shift from reshoring bets to AI infrastructure plays, specifically power, cooling, and ...

Trump's tariff roadmap for generic drug imports is aimed at encouraging pharmaceutical manufacturing in the US, with Indian ...

US President proposes zero tariff on imported generic medicines for two years before duties rise to 100% and later 200% to ...

Reshoring is happening at the same time manufacturers are running into delays reauthorizing skllled immigrant worker, as the ...

MISUMI Americas, a specification-driven sourcing partner for mechanical components and assemblies, today announced The Rise of U.S. Manufacturing report. U.S. manufacturing added hit a record $2.91 ...

A global survey from Parsec Automation found the high cost to scale AI was among the top concerns.

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but ...

The US tariff policy has been “wildly successful,” and the Trump administration was planning such measures to replace those overturned by the  Supreme Court, US Trade Representative Jamieson Greer ...

The Trump administration says its tariff drive has lowered the trade deficit and lifted reshoring. It is now seeking fresh legal routes to keep the policy alive after the Supreme Court setback.

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs ...